In vitro evaluation of biomarkers of nephrotoxicity through gene expression using gentamicin

Area of Science:

• Pharmacology
• Toxicology
• Molecular Biology

Background:

• Acute renal failure is a common adverse effect of medications.
• Current toxicity assessment methods lack predictive power for drug-induced kidney injury.
• Nephrotoxic drugs pose a significant risk to patient health.

Purpose of the Study:

• To evaluate the nephrotoxic effects of gentamicin on human kidney cells (HK-2 and HEK-293).
• To assess the utility of combined MTT assay, flow cytometry, and gene expression analysis in predicting drug nephrotoxicity.

Main Methods:

• Utilized MTT assay and flow cytometry to quantify cell viability and cell death (apoptosis and necrosis).
• Performed gene expression analysis to identify changes in key cellular biomarkers and signaling pathways.
• Investigated dose-dependent cytotoxic effects of gentamicin on HK-2 and HEK-293 cell lines.

Main Results:

• Gentamicin induced dose-dependent cytotoxicity, apoptosis, and necrosis in both cell lines.
• Observed increased expression of genes involved in cell death (TP53, CASP3, CASP8, CASP9) and kidney injury biomarkers (ICAM-1, KIM-1).
• Noted decreased expression of cell survival genes (BCL2L1) and growth factor (EGF).

Conclusions:

• Combined use of cell viability assays and gene expression profiling effectively evaluates the nephrotoxic potential of substances like gentamicin.
• Gene expression analysis provides insights into the molecular mechanisms of drug-induced kidney injury.
• This integrated approach offers a more predictive method for assessing drug safety.